A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus

Inclusion Criteria:

- Diagnosis of Lupus.

- Able and willing to have blood drawn for PK sampling.

Exclusion Criteria:

- Have severe active lupus nephritis.

- Have severe active central nervous system (CNS) or peripheral neurologic disease or
other severe neurologic involvement requiring treatment within approximately 3 months
prior to screening.

- Have received high dose corticosteroid within approximately 1 month prior to baseline.

- Have initiated or adjusted treatment with immunosuppressant drugs within approximately
1 month prior to baseline.

- Have received plasmapheresis within approximately 3 months prior to baseline.

- Have previously received approved or experimental B cell targeted therapies within the
last year.

- Have received any biologic or non-biologic therapy within approximately 3 months or 5
half-lives (whichever is longer).

- Have a history of severe reaction to any biologic therapy.

- Have an active or recent infection within approximately 1 month prior to Week 0.

- Have had a serious infection within approximately 3 month or serious bone/joint
infection within approximately 6 months prior to baseline.

- Have evidence of or test positive for active hepatitis B or are positive for hepatitis
C or human immunodeficiency virus (HIV).

- Have evidence of active or latent tuberculosis.

- Have significant hematological abnormalities.